These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 31821459)

  • 1. PTCy ameliorates GVHD by restoring regulatory and effector T-cell homeostasis in recipients with PD-1 blockade.
    Ikegawa S; Meguri Y; Kondo T; Sugiura H; Sando Y; Nakamura M; Iwamoto M; Maeda Y; Matsuoka KI
    Blood Adv; 2019 Dec; 3(23):4081-4094. PubMed ID: 31821459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved NK Cell Recovery Following Use of PTCy or Treg Expanded Donors in Experimental MHC-Matched Allogeneic HSCT.
    Wolf D; Barreras H; Copsel SN; Komanduri KV; Levy RB
    Transplant Cell Ther; 2022 Jun; 28(6):303.e1-303.e7. PubMed ID: 35302008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients.
    Hossain MS; Kunter GM; El-Najjar VF; Jaye DL; Al-Kadhimi Z; Taofeek OK; Li JM; Waller EK
    PLoS One; 2017; 12(9):e0184254. PubMed ID: 28953925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-transplant cyclophosphamide alters immune signatures and leads to impaired T cell reconstitution in allogeneic hematopoietic stem cell transplant.
    Zhao C; Bartock M; Jia B; Shah N; Claxton DF; Wirk B; Rakszawski KL; Nickolich MS; Naik SG; Rybka WB; Ehmann WCC; Hohl RJ; Valentin J; Bernas-Peterson M; Gerber EM; Zimmerman M; Mierski JA; Mineishi S; Zheng H
    J Hematol Oncol; 2022 May; 15(1):64. PubMed ID: 35590334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice.
    Ganguly S; Ross DB; Panoskaltsis-Mortari A; Kanakry CG; Blazar BR; Levy RB; Luznik L
    Blood; 2014 Sep; 124(13):2131-41. PubMed ID: 25139358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-Transplantation Cyclophosphamide Uniquely Restrains Alloreactive CD4
    Hadjis AD; Nunes NS; Khan SM; Fletcher RE; Pohl AP; Venzon DJ; Eckhaus MA; Kanakry CG
    Front Immunol; 2022; 13():796349. PubMed ID: 35242129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-transplant cyclophosphamide limits reactive donor T cells and delays the development of graft-versus-host disease in a humanized mouse model.
    Adhikary SR; Cuthbertson P; Nicholson L; Bird KM; Sligar C; Hu M; O'Connell PJ; Sluyter R; Alexander SI; Watson D
    Immunology; 2021 Oct; 164(2):332-347. PubMed ID: 34021907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superior immune reconstitution using Treg-expanded donor cells versus PTCy treatment in preclinical HSCT models.
    Wolf D; Bader CS; Barreras H; Copsel S; Pfeiffer BJ; Lightbourn CO; Altman NH; Komanduri KV; Levy RB
    JCI Insight; 2018 Oct; 3(20):. PubMed ID: 30333311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Posttransplant cyclophosphamide contributes to the impairment of the graft-versus-leukemia effect and the amelioration of graft-versus-host disease with the suppression of alloreactive T cells in a murine stem cell transplant model.
    Makuuchi Y; Nakashima Y; Nishimoto M; Koh H; Hino M; Nakamae H
    Exp Hematol; 2023 Jul; 123():56-65. PubMed ID: 37098360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Posttransplantation cyclophosphamide expands functional myeloid-derived suppressor cells and indirectly influences Tregs.
    Fletcher RE; Nunes NS; Patterson MT; Vinod N; Khan SM; Mendu SK; Li X; de Paula Pohl A; Wachsmuth LP; Choo-Wosoba H; Eckhaus MA; Venzon DJ; Kanakry CG
    Blood Adv; 2023 Apr; 7(7):1117-1129. PubMed ID: 36595377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disturbance in the reconstitution of distinct T-cell subsets and the incidence of GvHD following allo-HSCT in pediatric patients with non-malignant hematological disorders.
    Bayegi SN; Hamidieh AA; Behfar M; Bozorgmehr M; Saghazadeh A; Tajik N; Delbandi AA; Zavareh FT; Delavari S; Shekarabi M; Rezaei N
    Immunol Lett; 2023 Sep; 261():25-36. PubMed ID: 37474024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of Graft-versus-Host Disease Prevention by Post-transplantation Cyclophosphamide: An Evolving Understanding.
    Nunes NS; Kanakry CG
    Front Immunol; 2019; 10():2668. PubMed ID: 31849930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed death-1 pathway in host tissues ameliorates Th17/Th1-mediated experimental chronic graft-versus-host disease.
    Fujiwara H; Maeda Y; Kobayashi K; Nishimori H; Matsuoka K; Fujii N; Kondo E; Tanaka T; Chen L; Azuma M; Yagita H; Tanimoto M
    J Immunol; 2014 Sep; 193(5):2565-73. PubMed ID: 25080485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of donor CD4+CD25+ regulatory T cells on hematopoietic and immune reconstitution, GVHD and disease-free survival after allogeneic hematopoietic stem cell transplantation].
    Yang K; Fan ZP; Liu QF; Zhang Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Apr; 28(4):537-41. PubMed ID: 18495584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accumulation of T-cell-suppressive PD-L1
    Baur R; Karl F; Böttcher-Loschinski R; Stoll A; Völkl S; Gießl A; Flamann C; Bruns H; Schlötzer-Schrehardt U; Böttcher M; Schewe DM; Fischer T; Jitschin R; Mackensen A; Mougiakakos D
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36898735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marked in Vivo Donor Regulatory T Cell Expansion via Interleukin-2 and TL1A-Ig Stimulation Ameliorates Graft-versus-Host Disease but Preserves Graft-versus-Leukemia in Recipients after Hematopoietic Stem Cell Transplantation.
    Wolf D; Barreras H; Bader CS; Copsel S; Lightbourn CO; Pfeiffer BJ; Altman NH; Podack ER; Komanduri KV; Levy RB
    Biol Blood Marrow Transplant; 2017 May; 23(5):757-766. PubMed ID: 28219835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy.
    Asano T; Meguri Y; Yoshioka T; Kishi Y; Iwamoto M; Nakamura M; Sando Y; Yagita H; Koreth J; Kim HT; Alyea EP; Armand P; Cutler CS; Ho VT; Antin JH; Soiffer RJ; Maeda Y; Tanimoto M; Ritz J; Matsuoka KI
    Blood; 2017 Apr; 129(15):2186-2197. PubMed ID: 28151427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recipient-Derived Allo-iTregs Induced by Donor DCs Effectively Inhibit the Proliferation of Donor T Cells and Reduce GVHD.
    Yang ZG; Wen RT; Feng JS; Cao PJ; Zhou HT; Liu WX
    Anat Rec (Hoboken); 2019 May; 302(5):825-836. PubMed ID: 30312018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reconstitution of Th17, Tc17 and Treg cells after paediatric haematopoietic stem cell transplantation: Impact of interleukin-7.
    Kielsen K; Ryder LP; Lennox-Hvenekilde D; Gad M; Nielsen CH; Heilmann C; Ifversen M; Pedersen AE; Müller K
    Immunobiology; 2018 Feb; 223(2):220-226. PubMed ID: 29033080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Influence of donor T(reg) cells on GVHD and hematopoietic reconstitution after allogeneic bone marrow transplantation in mice].
    Yang K; Liu QF; Fan ZP; Zhang Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Jun; 15(3):547-52. PubMed ID: 17605863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.